Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 6/20 | 0.36 |
| ▸ | TAS1R1 | Q7RTX1 | 6/20 | 0.36 |
| ▸ | TAS1R2 | Q8TE23 | 6/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 5/20 | 0.36 |
| ▸ | ACHE | P22303 | 3/20 | 0.35 |
| ▸ | MAOA | P21397 | 3/20 | 0.35 |
| ▸ | MAOB | P27338 | 3/20 | 0.35 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | BCHE | P06276 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22501502 | 1.00 | TAS1R3 (0.36) | TAS1R3TAS1R1TAS1R2TRPV1ACHE | |
| SCHEMBL13857734 | 0.93 | TAS1R3 (0.44) | TAS1R3TAS1R1TAS1R2LMNA | |
| SCHEMBL1886442 | 0.86 | TAS1R3 (0.34) | TAS1R3TAS1R1TAS1R2TRPV1ACHE | |
| SCHEMBL1878236 | 0.84 | GAA (0.36) | TAS1R3TAS1R1TAS1R2TRPV1ACHE | |
| SCHEMBL1875351 | 0.84 | GAA (0.36) | TAS1R3TAS1R1TAS1R2TRPV1ACHE | |
| SCHEMBL1875354 | 0.84 | GAA (0.36) | TAS1R3TAS1R1TAS1R2TRPV1ACHE | |
| SCHEMBL29771969 | 0.84 | GAA (0.36) | TAS1R3TAS1R1TAS1R2TRPV1ACHE | |
| SCHEMBL12402632 | 0.83 | PDPK1 (0.43) | MAOAMAOB | |
| SCHEMBL12402626 | 0.83 | PDPK1 (0.43) | MAOAMAOB | |
| SCHEMBL13860101 | 0.80 | TRPV1 (0.39) | TAS1R3TAS1R1TAS1R2TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2706999-B1 | SELECTIVE HETEROCYCLIC SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS | CELGENE INT II SARL (CH) | 2019-08-28 | — | — | EP | disclosed |
| EP-2498609-B1 | SELECTIVE HETEROCYCLIC SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS | CELGENE INT II SARL (CH) | 2018-04-18 | — | — | EP | disclosed |
| WO-2012158550-A9 | SELECTIVE HETEROCYCLIC SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS | RECEPTOS, INC. (US) | 2017-10-26 | — | — | WO | disclosed |
| US-9481659-B2 | Selective heterocyclic sphingosine 1 phosphate receptor modulators | CELGENE INTERNATIONAL II SÀRL (CH) | 2016-11-01 | — | — | US | disclosed |
| US-20150299179-A1 | SELECTIVE HETEROCYCLIC SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS | RECEPTOS, INC. (US) | 2015-10-22 | — | — | US | disclosed |
| US-20150252037-A1 | SELECTIVE HETEROCYCLIC SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS | RECEPTOS LLC | 2015-09-10 | — | — | US | disclosed |
| EP-2706999-A2 | SELECTIVE HETEROCYCLIC SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS | Receptos, Inc. (US) | 2014-03-19 | — | — | EP | disclosed |
| US-20140039183-A1 | SELECTIVE HETEROCYCLIC SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS | RECEPTOS LLC | 2014-02-06 | — | — | US | disclosed |
| WO-2012158550-A2 | SELECTIVE HETEROCYCLIC SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS | RECEPTOS, INC. (US) | 2012-11-22 | — | — | WO | disclosed |
| EP-2498609-A1 | SELECTIVE HETEROCYCLIC SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS | Receptos, Inc. (US) | 2012-09-19 | — | — | EP | disclosed |
| WO-2011060391-A1 | SELECTIVE HETEROCYCLIC SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS | RECEPTOS, INC. (US) | 2011-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140039183-A1 | SELECTIVE HETEROCYCLIC SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS | S1PR1, S1PR3, S1PR2 | TAS1R3 2046/4885TAS1R1 1302/4885TAS1R2 1816/4885 |
| US-20150252037-A1 | SELECTIVE HETEROCYCLIC SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS | S1PR1, S1PR3, S1PR2 | TAS1R3 2046/4885TAS1R1 1302/4885TAS1R2 1816/4885 |
| US-20150299179-A1 | SELECTIVE HETEROCYCLIC SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS | S1PR1, S1PR3, S1PR2 | TAS1R3 2018/4885TAS1R1 1288/4885TAS1R2 1803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.